WO2008006363A3 - Behandlung von t-zell-malignomen mit bcl11b-inhibitoren - Google Patents
Behandlung von t-zell-malignomen mit bcl11b-inhibitoren Download PDFInfo
- Publication number
- WO2008006363A3 WO2008006363A3 PCT/DE2007/001266 DE2007001266W WO2008006363A3 WO 2008006363 A3 WO2008006363 A3 WO 2008006363A3 DE 2007001266 W DE2007001266 W DE 2007001266W WO 2008006363 A3 WO2008006363 A3 WO 2008006363A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bcl11b
- inhibitors
- treatment
- cell carcinomas
- carcinomas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Die vorliegende Erfindung betrifft die Verwendung von BCL11b-Inhibitoren zur Behandlung von T-Zell-Malignomen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006032424A DE102006032424A1 (de) | 2006-07-13 | 2006-07-13 | Behandlung von T-Zell-Malignomen |
DE102006032424.2 | 2006-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008006363A2 WO2008006363A2 (de) | 2008-01-17 |
WO2008006363A3 true WO2008006363A3 (de) | 2008-06-26 |
Family
ID=38825234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2007/001266 WO2008006363A2 (de) | 2006-07-13 | 2007-07-13 | Behandlung von t-zell-malignomen mit bcl11b-inhibitoren |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102006032424A1 (de) |
WO (1) | WO2008006363A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071815B2 (en) | 2008-07-17 | 2011-12-06 | Arup Kumar Indra | CTIP2 expression in squamous cell carcinoma |
CN103409466B (zh) * | 2013-05-27 | 2015-01-21 | 中国科学院广州生物医药与健康研究院 | 一种使bcl11b蛋白降解的方法 |
WO2017192959A2 (en) * | 2016-05-05 | 2017-11-09 | The Research Foundation For The State University Of New York | Therapeutically modulating apob and apoai |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008583A2 (en) * | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2005045035A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
-
2006
- 2006-07-13 DE DE102006032424A patent/DE102006032424A1/de not_active Withdrawn
-
2007
- 2007-07-13 WO PCT/DE2007/001266 patent/WO2008006363A2/de active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
Non-Patent Citations (4)
Title |
---|
CISMASIU V B ET AL: "BCL11B functionally associates with the NuRD complex in T lymphocates to repress targeted promotor", ONCOGENE, vol. 24, 2005, pages 6753 - 6764, XP002475287 * |
GRABARCZYK P. ET AL: "Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells", ONCOGENE, vol. 26, 2007, pages 3797 - 3810, XP002475284 * |
MACLEOD RAF ET AL: "BCL11B rearragemants probably target T-cell neoplasia rather than acute myelocytic leukemia", CANCER GENETICS AND CYTOGENETICS, vol. 153, 2004, pages 88 - 89, XP002475285 * |
OSHIRO A. ET AL: "Identification of subtype-specific genomic alterations in aggrsessive adult T-cell leukemia/lymphoma", BLOOD, vol. 107, no. 11, June 2006 (2006-06-01), pages 4500 - 4507, XP002475286 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008006363A2 (de) | 2008-01-17 |
DE102006032424A1 (de) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
AU2007228570A8 (en) | Treatment of CNS conditions | |
WO2009052431A3 (en) | Cd19 binding agents and uses thereof | |
WO2008033836A3 (en) | Process and intermediates for preparing integrase inhibitors | |
WO2007095638A3 (en) | Boron-containing small molecules as anti-inflammatory agents | |
WO2008067219A3 (en) | Quinazolinone modulators of tgr5 | |
AP2008004436A0 (en) | Odcase inhibitors for the treatment of malaria | |
WO2008112199A8 (en) | Method for inhibiting topoisomerase ii | |
WO2008097561A8 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
WO2008112192A3 (en) | Epha3 antibodies for the treatment of solid tumors | |
MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
WO2008002855A8 (en) | Methods for the treatment of wounds | |
WO2007106915A3 (en) | Antibodies to egfl7 and methods for their use | |
WO2008053334A3 (en) | An improved process for preparing rosuvastatin calcium | |
WO2008021346A3 (en) | Pure paliperidone and processes for preparing thereof | |
TW200734339A (en) | Forms of dolasetron mesylate and processes for their preparation | |
WO2008075205A3 (en) | Improved process for the preparation of voriconazole | |
WO2008060693A3 (en) | Tetracyclic imidazole analogs | |
WO2007146813A3 (en) | Pyridinone analogs as cell proliferation inhibitors | |
ZA200808011B (en) | Process for the isolation of calliterpenone (16alpha, 17-DiHyDroxy-S-Oxo-Phyllocladane) | |
WO2010148177A3 (en) | Compounds, compositions, methods of synthesis, and methods of treatment | |
WO2008006363A3 (de) | Behandlung von t-zell-malignomen mit bcl11b-inhibitoren | |
WO2008085927A3 (en) | Methods, compositions, and kits for the treatment of pain | |
WO2007064997A3 (en) | Compounds and methods for inhibiting apoptosis | |
WO2008103431A3 (en) | Dnai - liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07785638 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07785638 Country of ref document: EP Kind code of ref document: A2 |